Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Chemo-PHREE Trial: Cemiplimab in Resectable NSCLC
NCT07746388Phase 2Recruiting
- Sponsor
- University of Maryland, Baltimore
- Start
- Sep 2026
- Primary completion
- Sep 2030
- Countries
- 1
01
Overview
A Phase 2 trial of cemiplimab in non-small cell lung cancer (NSCLC), sponsored by University of Maryland, Baltimore. Started Sep 2026; status: recruiting.
02
Drugs
cemiplimab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT07746388.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07746388.